The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The TRANQUILITY 2 Trial: Multi-Center Randomized, Double-Masked, Parallel Design,
Vehicle-Controlled Phase 2/3 Clinical Trial to Assess the Efficacy and Safety of 0.25%
Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease